The relationship between adenosine deaminase and heart rate-corrected QT interval in type 2 diabetic patients

Lu, Chunfeng; Ge, Xun; Su, Jianbin; Wang, Xueqin; Zhang, Dongmei; Xu, Feng; Liu, Wangshu; Min, Su

doi:10.1530/ec-21-0199

Cited by 2 publications

(2 citation statements)

References 39 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, patients with increased cardiometabolic risks are always characterized by elevated serum ADA levels, and these cardiometabolic risks include higher BMI (35), increased TC (36), hypertension (16), atherosclerosis (13), thrombosis (14), coronary artery calcification (37) and T2D (38). Furthermore, in our previous studies and other previous studies, elevated serum ADA levels are not only involved in impaired pancreatic b-cell function in T2D (39) but also contribute to several diabetic complications, such as diabetic retinopathy (40), diabetic nephropathy (41), and prolonged heart QT interval in T2D (42). In our present study, serum ADA levels were observed to be positively correlated with ageing, higher SBP, longer diabetes duration, and increased levels of ALT, AST, GGT, CysC and HbA1c and negatively correlated with eGFR and insulin sensitivity index (IS-CP).…”

Section: Discussionmentioning

confidence: 71%

Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes

Zhuang

et al. 2022

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

BackgroundIncreased serum adenosine deaminase (ADA) levels have been shown to be involved in metabolic abnormalities and immune disequilibrium, which may in turn contribute to inflammatory diseases. This study aimed to determine whether increased serum ADA levels are related to diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes (T2D).MethodsThis study was part of a series exploring the potential risks for DPN. All patients received DPN assessment based on neuropathic symptoms, neuropathic signs, and nerve conduction studies to calculate the composite Z score of nerve latency, amplitude and conduction velocity (NCV). DPN was confirmed by both at least a presentation of neuropathic symptoms/signs and an abnormal nerve conduction index. Serum ADA levels were also synchronously detected.ResultsA total of 384 eligible patients with T2D were recruited for this study, and 24.5% (n=94) were determined to have DPN. Increases in serum ADA levels were closely associated with increases in composite Z score of latency (β=0.263, t=5.273, p<0.001) and decreases in composite Z score of amplitude (β=–0.126, t=–2.352, p=0.019) and NCV (β=–0.201, t=–3.841, p<0.001) after adjusting for other clinical covariates. Moreover, each 5 U/L increase in serum ADA levels was associated with a 1.781-fold increased adjusted odds ratio of having DPN (95% confidence interval: 1.271–2.495). Furthermore, the optimal cut-off value of serum ADA levels to discriminate DPN was ≥14.2 U/L (sensitivity=59.57%, specificity=75.52% and Youden index=0.351) after analysis by receiver operating characteristic curve.ConclusionsIncreased serum ADA levels may be a potential risk factor for DPN in patients with T2D.

show abstract

Section: Discussionmentioning

confidence: 71%

Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes

Zhuang

et al. 2022

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The CHD was independently associated with QTc interval prolongation even after adjustment for age and sex [ 7 ]. A recent study found that female gender and treatment with insulin sensitizers were the independent contributors for QTc interval prolongation [ 8 ]. QTc was found to independently predict all-cause mortality in a prospective cohort of people with type 2 diabetes [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of QT prolongation and its risk factors in patients with type 2 diabetes

et al. 2023

View full text Add to dashboard Cite

Background QT prolongation increases cardiovascular mortality in diabetes. The risk factors for QT prolongation vary across different studies. There is no data on the QT prolongation in patients with diabetes from the Arab region, where diabetes is highly prevalent. Here we aimed to assess the prevalence of QT prolongation and its associated risk factors in patients with type 2 diabetes from Saudi Arabia. Method This was a retrospective, cross-sectional, hospital-based file review study. Data were collected from the medical records of patients with type 2 diabetes aged above 14 years and underwent ECG examination, and laboratory investigations were done within one month of ECG. Results The study included 782 patients with a prevalence of QTc prolongation of 13%. Patients with prolonged QTc interval were characterized by older age, higher BMI, longer diabetes duration, lower total cholesterol and LDL-C, and more diabetic nephropathy, hypertension, and CVD cases. They were also more in insulin treatment, antihypertensive medications, loop diuretics, and potassium-sparring diuretics. Logistic regression analysis revealed the odds of prolonged QTc interval increased significantly with CVD (OR = 1.761, 95% CI:1.021–3.036, p = 0.042), and usage of loop diuretics (OR = 2.245, 95% CI:1.023–4.923, p = 0.044) after adjusting for age, gender, and duration of diabetes. Conclusion The risk factors associated with QTc prolongation in patients with type 2 diabetes are CVD, and loop diuretics. Age, BMI, and diabetes duration were more in people with QTc prolongation, whereas total cholesterol and LDL-C levels were lower. More patients had diabetic nephropathy, hypertension, and CVD with prolonged QTc.

show abstract

The relationship between adenosine deaminase and heart rate-corrected QT interval in type 2 diabetic patients

Cited by 2 publications

References 39 publications

Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes

Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes

Prevalence of QT prolongation and its risk factors in patients with type 2 diabetes

Contact Info

Product

Resources

About